XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.21.2

Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Schedule of Derivative Liabilities at Fair Value | The following table presents the changes in the development derivative liability for the three and nine months ended September 30, 2021:
|  | Three Months Ended September 30, 2021 |  | Nine Months Ended September 30, 2021
Fair value at beginning of period |  | $ | 11,607 |  |  | $ | — |
Non-cash research and development expense |  | 5,702 |  |  | 11,497 |
Cash receipts from SFJ |  | 750 |  |  | 2,250 |
Change in the fair value of development derivative liability |  | 3,328 |  |  | 7,640 |
Fair value at end of period |  | $ | 21,387 |  |  | $ | 21,387 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration